Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Beth A. Tippett Barr is active.

Publication


Featured researches published by Beth A. Tippett Barr.


Clinical Infectious Diseases | 2012

Multidrug-Resistant Typhoid Fever With Neurologic Findings on the Malawi-Mozambique Border

Emily Lutterloh; Andrew Likaka; James J. Sejvar; Robert Manda; Jeremias Naiene; Stephan S. Monroe; Tadala Khaila; Benson Chilima; Macpherson Mallewa; Sam Kampondeni; Sara A. Lowther; Linda Capewell; Kashmira Date; David Townes; Yanique Redwood; Joshua G. Schier; Benjamin Nygren; Beth A. Tippett Barr; Austin Demby; Abel Phiri; Rudia Lungu; James Kaphiyo; Michael Humphrys; Deborah F. Talkington; Kevin Joyce; Lauren J. Stockman; Gregory L. Armstrong; Eric D. Mintz

BACKGROUND Salmonella enterica serovar Typhi causes an estimated 22 million cases of typhoid fever and 216 000 deaths annually worldwide. We investigated an outbreak of unexplained febrile illnesses with neurologic findings, determined to be typhoid fever, along the Malawi-Mozambique border. METHODS The investigation included active surveillance, interviews, examinations of ill and convalescent persons, medical chart reviews, and laboratory testing. Classification as a suspected case required fever and ≥1 other finding (eg, headache or abdominal pain); a probable case required fever and a positive rapid immunoglobulin M antibody test for typhoid (TUBEX TF); a confirmed case required isolation of Salmonella Typhi from blood or stool. Isolates underwent antimicrobial susceptibility testing and subtyping by pulsed-field gel electrophoresis (PFGE). RESULTS We identified 303 cases from 18 villages with onset during March-November 2009; 214 were suspected, 43 were probable, and 46 were confirmed cases. Forty patients presented with focal neurologic abnormalities, including a constellation of upper motor neuron signs (n = 19), ataxia (n = 22), and parkinsonism (n = 8). Eleven patients died. All 42 isolates tested were resistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole; 4 were also resistant to nalidixic acid. Thirty-five of 42 isolates were indistinguishable by PFGE. CONCLUSIONS The unusual neurologic manifestations posed a diagnostic challenge that was resolved through rapid typhoid antibody testing in the field and subsequent blood culture confirmation in the Malawi national reference laboratory. Extending laboratory diagnostic capacity, including blood culture, to populations at risk for typhoid fever in Africa will improve outbreak detection, response, and clinical treatment.


PLOS ONE | 2012

Neurologic Manifestations Associated with an Outbreak of Typhoid Fever, Malawi - Mozambique, 2009: An Epidemiologic Investigation

James J. Sejvar; Emily Lutterloh; Jeremias Naiene; Andrew Likaka; Robert Manda; Benjamin Nygren; Stephan S. Monroe; Tadala Khaila; Sara A. Lowther; Linda Capewell; Kashmira Date; David Townes; Yanique Redwood; Joshua G. Schier; Beth A. Tippett Barr; Austin Demby; Macpherson Mallewa; Sam Kampondeni; Ben Blount; Michael Humphrys; Deborah F. Talkington; Gregory L. Armstrong; Eric D. Mintz

Background The bacterium Salmonella enterica serovar Typhi causes typhoid fever, which is typically associated with fever and abdominal pain. An outbreak of typhoid fever in Malawi-Mozambique in 2009 was notable for a high proportion of neurologic illness. Objective Describe neurologic features complicating typhoid fever during an outbreak in Malawi-Mozambique Methods Persons meeting a clinical case definition were identified through surveillance, with laboratory confirmation of typhoid by antibody testing or blood/stool culture. We gathered demographic and clinical information, examined patients, and evaluated a subset of patients 11 months after onset. A sample of persons with and without neurologic signs was tested for vitamin B6 and B12 levels and urinary thiocyanate. Results Between March – November 2009, 303 cases of typhoid fever were identified. Forty (13%) persons had objective neurologic findings, including 14 confirmed by culture/serology; 27 (68%) were hospitalized, and 5 (13%) died. Seventeen (43%) had a constellation of upper motor neuron findings, including hyperreflexia, spasticity, or sustained ankle clonus. Other neurologic features included ataxia (22, 55%), parkinsonism (8, 20%), and tremors (4, 10%). Brain MRI of 3 (ages 5, 7, and 18 years) demonstrated cerebral atrophy but no other abnormalities. Of 13 patients re-evaluated 11 months later, 11 recovered completely, and 2 had persistent hyperreflexia and ataxia. Vitamin B6 levels were markedly low in typhoid fever patients both with and without neurologic signs. Conclusions Neurologic signs may complicate typhoid fever, and the diagnosis should be considered in persons with acute febrile neurologic illness in endemic areas.


Journal of Acquired Immune Deficiency Syndromes | 2017

Lessons Learned From Option B+ in the Evolution Toward “Test and Start” From Malawi, Cameroon, and the United Republic of Tanzania

Thokozani Kalua; Beth A. Tippett Barr; Joep J. van Oosterhout; Dorothy Mbori-Ngacha; Erik J Schouten; Sundeep Gupta; Amakobe Sande; Gerald Zomba; Hannock Tweya; Edgar Lungu; Deborah Kajoka; Pius M. Tih; Andreas Jahn

Abstract: The acceleration of prevention of mother-to-child transmission (PMTCT) activities, coupled with the rollout of 2010 World Health Organization (WHO) guidelines, led to important discussions and innovations at global and country levels. One paradigm-shifting innovation was Option B+ in Malawi. It was later included in WHO guidelines and eventually adopted by all 22 Global Plan priority countries. This article presents Malawis experience with designing and implementing Option B+ and provides complementary narratives from Cameroon and Tanzania. Malawis HIV program started in 2002, but by 2009, the PMTCT program was lagging far behind the antiretroviral therapy (ART) program because of numerous health system challenges. When WHO recommended Option A and Option B for PMTCT in 2010, it was clear that Malawis HIV program would not be able to successfully implement either option without increasing existing barriers to PMTCT services and potentially decreasing womens access to care. Subsequent stakeholder discussions led to the development of Option B+. Operationalizing Option B+ required several critical considerations, including the complete integration of ART and PMTCT programs, systematic reduction of barriers to facilitate doubling the number of ART sites in less than a year, building consensus with stakeholders, and securing additional resources for the new program. During the planning and implementation process, several lessons were learned which are considerations for countries transitioning to “treat-all”: Comprehensive change requires effective government leadership and coordination; national clinical guidelines must accommodate health system limitations; ART services and commodities should be decentralized within facilities; the general public should be well informed about major changes in the national HIV program; and patients should be educated on clinic processes to improve program monitoring.


Journal of Acquired Immune Deficiency Syndromes | 2016

Safety, feasibility, and acceptability of the prepex device for adult male circumcision in Malawi

Pamela K. Kohler; Beth A. Tippett Barr; Anderson Kang'ombe; Carola Hofstee; Franklin Kilembe; Sean Galagan; David Chilongozi; Dorothy Namate; Medson Machaya; Khuliena Kabwere; Mwawi Mwale; Wezi Msunguma; Jason T. Reed; Frank Chimbwandira

Introduction:Nonsurgical adult male circumcision devices present an alternative to surgery where health resources are limited. This study aimed to assess the safety, feasibility, and acceptability of the PrePex device for adult male circumcision in Malawi. Methods:A prospective single-arm cohort study was conducted at 3 sites (1 urban static, 1 rural static, 1 rural tent) in Malawi. Adverse event (AE) outcomes were stratified to include/exclude pain, and confidence intervals (CIs) were corrected for clinic-level clustering. Results:Among 935 men screened, 131 (14.0%) were not eligible, 13 (1.4%) withdrew before placement, and 791 (84.6%) received the device. Moderate and severe AEs totaled 7.1% including pain [95% CI: 3.4–14.7] and 4.0% excluding pain (95% CI: 2.6 to 6.4). Severe AEs included pain (n = 3), insufficient skin removal (n = 4), and early removal (n = 4). Among early removals, 1 had immediate surgical circumcision, 1 had surgery after 48 hours of observation, 1 declined surgery, and 1 did not return to our site although presented at a nearby clinic. More than half of men (51.9%) reported odor; however, few (2.2%) stated they would not recommend the device to others because of odor. Median levels of reported pain (scale, 1–10) were 2 (interquartile range, 2–4) during application and removal, and 0 (interquartile range, 0–2) at all other time points. Conclusions:Severe AEs were rare and similar to other programs. Immediate provision of surgical services after displacement or early removal proved a challenge. Cases of insufficient skin removal were linked to poor technique, suggesting provider training requires reinforcement and supervision.


PLOS ONE | 2018

HIV infection in patients with sexually transmitted infections in Zimbabwe – Results from the Zimbabwe STI etiology study

Peter H. Kilmarx; Elizabeth Gonese; David A. Lewis; Z. Mike Chirenje; Beth A. Tippett Barr; Ahmed S. Latif; Lovemore Gwanzura; H. Hunter Handsfield; Anna Machiha; Owen Mugurungi; Cornelius A. Rietmeijer

Background HIV and other sexually transmitted infections (STI) frequently co-occur. We conducted HIV diagnostic testing in an assessment of the etiologies of major STI syndromes in Zimbabwe. Methods A total of 600 patients were enrolled at six geographically diverse, high-volume STI clinics in Zimbabwe in 2014–15: 200 men with urethral discharge, 200 women with vaginal discharge, and 100 men and 100 women each with genital ulcer disease (GUD). Patients completed a questionnaire, underwent a genital examination, and had specimens taken for etiologic testing. Patients were offered, but not required to accept, HIV testing using a standard HIV algorithm in which two rapid tests defined a positive result. Results A total of 489 participants (81.5%) accepted HIV testing; 201 (41.1%) tested HIV-1-positive, including 16 (11.9%) of 134 participants who reported an HIV-negative status at study enrollment, and 58 (28.2%) of 206 participants who reported their HIV status as unknown. Of 147 who self-reported being HIV-positive at study enrollment, 21 (14.3%) tested HIV negative. HIV infection prevalence was higher in women (47.3%) than in men (34.8%, p<0.01), and was 28.5% in men with urethral discharge, 40.5% in women with vaginal discharge, 45.2% in men with GUD, and 59.8% in women with GUD (p<0.001). Conclusions The high prevalence of HIV infection in STI clinic patients in Zimbabwe underscores the importance of providing HIV testing and referral for indicated prevention and treatment services for this population. The discrepancy between positive self-reported and negative study HIV test results highlights the need for operator training, strict attention to laboratory quality assurance, and clear communication with patients about their HIV infection status.


Morbidity and Mortality Weekly Report | 2018

Notes from the Field : Outbreak of Vibrio cholerae Associated with Attending a Funeral — Chegutu District, Zimbabwe, 2018

Jarred B. McAteer; Sydney Danda; Tonderai Nhende; Paul Manamike; Tonderai Parayiwa; Andrew Tarupihwa; Ottias Tapfumanei; Portia Manangazira; Gibson Mhlanga; Daniela B. Garone; Andrea Martinsen; Rachael D. Aubert; William W. Davis; Rupa Narra; Shirish Balachandra; Beth A. Tippett Barr; Eric D. Mintz

Outbreak of Vibrio cholerae Associated with Attending a Funeral — Chegutu District, Zimbabwe, 2018 Jarred B. McAteer, MD1,2; Sydney Danda, MSc3; Tonderai Nhende3; Paul Manamike3; Tonderai Parayiwa4; Andrew Tarupihwa5; Ottias Tapfumanei6; Portia Manangazira, MPH6; Gibson Mhlanga, MD6; Daniela B. Garone, MD7; Andrea Martinsen, MPH8; Rachael D. Aubert, PhD2; William Davis, DrPH1,2, Rupa Narra, MD2; Shirish Balachandra, MD9; Beth A. Tippett Barr, DrPH9; Eric Mintz, MD2


Sexually Transmitted Diseases | 2017

The Etiology of Genital Ulcer Disease and Coinfections With Chlamydia trachomatis and Neisseria gonorrhoeae in Zimbabwe: Results From the Zimbabwe STI Etiology Study

More Mungati; Anna Machiha; Owen Mugurungi; Mufuta Tshimanga; Peter H. Kilmarx; Justice Nyakura; Gerald Shambira; Vitalis Kupara; David A. Lewis; Elizabeth Gonese; Beth A. Tippett Barr; H. Hunter Handsfield; Cornelis A. Rietmeijer

Background In many countries, sexually transmitted infections (STIs) are treated syndromically. Thus, patients diagnosed as having genital ulcer disease (GUD) in Zimbabwe receive a combination of antimicrobials to treat syphilis, chancroid, lymphogranuloma venereum (LGV), and genital herpes. Periodic studies are necessary to assess the current etiology of GUD and assure the appropriateness of current treatment guidelines. Materials and Methods We selected 6 geographically diverse clinics in Zimbabwe serving high numbers of STI cases to enroll men and women with STI syndromes, including GUD. Sexually transmitted infection history and risk behavioral data were collected by questionnaire and uploaded to a Web-based database. Ulcer specimens were obtained for testing using a validated multiplex polymerase chain reaction (M-PCR) assay for Treponema pallidum (TP; primary syphilis), Haemophilus ducreyi (chancroid), LGV-associated strains of Chlamydia trachomatis, and herpes simplex virus (HSV) types 1 and 2. Blood samples were collected for testing with HIV, treponemal, and nontreponemal serologic assays. Results Among 200 GUD patients, 77 (38.5%) were positive for HSV, 32 (16%) were positive for TP, and 2 (1%) were positive for LGV-associated strains of C trachomatis. No H ducreyi infections were detected. No organism was found in 98 (49.5%) of participants. The overall HIV positivity rate was 52.2% for all GUD patients, with higher rates among women compared with men (59.8% vs 45.2%, P < 0.05) and among patients with HSV (68.6% vs 41.8%, P < 0.0001). Among patients with GUD, 54 (27.3%) had gonorrhea and/or chlamydia infection. However, in this latter group, 66.7% of women and 70.0% of men did not have abnormal vaginal or urethral discharge on examination. Conclusions Herpes simplex virus is the most common cause of GUD in our survey, followed by T. pallidum. No cases of chancroid were detected. The association of HIV infections with HSV suggests high risk for cotransmission; however, some HSV ulcerations may be due to HSV reactivation among immunocompromised patients. The overall prevalence of gonorrhea and chlamydia was high among patients with GUD and most of them did not meet the criteria for concomitant syndromic management covering these infections.


Open Forum Infectious Diseases | 2017

Moderate Levels of Pre-Treatment HIV Drug Resistance — Zimbabwe, April–July 2015

Juliana da Silva; Janet Dzangare; Elizabeth Gonese; Mutsa Mhangara; Owen Mugurungi; Beth A. Tippett Barr; Spencer Lloyd; Elliot Raizes

Abstract Background The World Health Organization (WHO) HIV Drug Resistance (HIVDR) report 2012 demonstrated that the levels of HIVDR to first-line antiretroviral therapy (ART) are increasing. This finding threatens to reverse a decade of gains in HIV/AIDS epidemic control. The WHO Global Action Plan for HIVDR emphasizes strengthening surveillance of drug resistance through the implementation of national cross-sectional surveys. We conducted such survey to determine the prevalence of HIVDR among ART-naive patients in Zimbabwe and to describe the profile of the surveillance drug resistance mutations (SDRM) encountered in the country. Methods A prospective, nationally representative, cross-sectional survey was conducted in 35 clinical sites selected using two stage probability proportional to size sampling. Patients were enrolled during April–July 2015. Specimens were sent for genotyping to CDC Atlanta. SDRM were interpreted using Stanford HIV Drug Resistance Database classification. Results A total of 361 subjects were surveyed. Most participants were female (60.3%) and the median age was 35.8 years. Thirty-four out of 361subjects presented with ≥1 SDRM (9.4%, 95% confidence interval: 6.8–12.8%) prior to initiation antiretroviral therapy (ART). Non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations were the most commonly detected mutation (n = 30). Only two patients presented with a nucleoside reverse transcriptase inhibitor mutation and one patient presented with a protease inhibitor mutation. In two patients, ≥3 SDRMs were detected, which may suggest they were not truly ART-naïve. Conclusion This study provides national estimates of HIVDR in a high burden country with broad access to ART and provides valuable inisight on the state of HIVDR in such setting. Zimbabwe has reached moderate levels of HIVDR in ART-naive patients, as specified by the WHO classification. These levels may impact the ability to achieve viral suppression in a significant number of patients initiating standard ART regimens in Zimbabwe, where NNRTI-based regimens are used as the first line. The use of drugs with high resistance barrier, such as dolutegravir, may improve the care of patients in the developing world, where individualized pretreatment genotype is not feasible. Disclosures All authors: No reported disclosures.


Journal of Exposure Science and Environmental Epidemiology | 2012

Consumption of pesticide-treated wheat seed by a rural population in Malawi

Joshua G. Schier; James J. Sejvar; Emily Lutterloh; Andrew Likaka; Eugenia Katsoudas; Yelena D Karaseva; Beth A. Tippett Barr; Yanique Redwood; Stephan S. Monroe

An outbreak of typhoid fever in rural Malawi triggered an investigation by the Malawi Ministry of Health and the Centers for Disease Control and Prevention in July 2009. During the investigation, villagers were directly consuming washed, donated, pesticide-treated wheat seed meant for planting. The objective of this study was to evaluate the potential for pesticide exposure and health risk in the outbreak community. A sample of unwashed (1430 g) and washed (759 g) wheat seed donated for planting, but which would have been directly consumed, was tested for 365 pesticides. Results were compared with each other (percentage change), the US Environmental Protection Agencys (EPA) health guidance values and estimated daily exposures were compared with their Reference dose (RfD). Unwashed and washed seed samples contained, respectively: carboxin, 244 and 57 p.p.m.; pirimiphos methyl, 8.18 and 8.56 p.p.m.; total permethrin, 3.62 and 3.27 p.p.m.; and carbaryl, 0.057 and 0.025 p.p.m.. Percentage change calculations (unwashed to washed) were as follows: carboxin, −76.6%; pirimiphos methyl, +4.6%; total permethrin, −9.7%; and carbaryl −56.1%. Only carboxin and total permethrin concentration among washed seed samples exceeded US EPA health guidance values (285 × and seven times, respectively). Adult estimated exposure scenarios (1 kg seed) exceeded the RfD for carboxin (8 × ) and pirimiphos methyl (12 × ). Adult villagers weighing 70 kg would have to consume 0.123, 0.082, 1.06, and 280 kg of washed seed daily to exceed the RfD for carboxin, pirimiphos methyl, permethrins, and carbaryl, respectively. Carboxin, pirimiphos methyl, permethrins, and carbaryl were detected in both unwashed and washed samples of seed. Carboxin, total permethrin, and carbaryl concentration were partially reduced by washing. Health risks from chronic exposure to carboxin and pirimiphos methyl in these amounts are unclear. The extent of this practice among food insecure communities receiving relief seeds and resultant health impact needs further study.


Morbidity and Mortality Weekly Report | 2013

Impact of an innovative approach to prevent mother-to-child transmission of HIV - Malawi, July 2011-September 2012

Frank Chimbwandira; Eustice Mhango; Simon D. Makombe; Dalitso Midiani; Charles Mwansambo; Joseph Njala; Zengani Chirwa; Andreas Jahn; Erik J Schouten; B. Ryan Phelps; Anna Gieselman; Alice Maida; Sundeep Gupta; Beth A. Tippett Barr; Surbhi Modi; Helen Dale; John Aberle-Grasse; Margarett Davis; David M. Bell; James C. Houston

Collaboration


Dive into the Beth A. Tippett Barr's collaboration.

Top Co-Authors

Avatar

Eric D. Mintz

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Owen Mugurungi

Ministry of Health and Child Welfare

View shared research outputs
Top Co-Authors

Avatar

Emily Lutterloh

New York State Department of Health

View shared research outputs
Top Co-Authors

Avatar

James J. Sejvar

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Joshua G. Schier

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Peter H. Kilmarx

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Stephan S. Monroe

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Yanique Redwood

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Austin Demby

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge